Evidence map›Paper›PMID 40832697›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Prevalence and risk factors of cerebral microhemorrhages and superficial siderosis in cognitively unimpaired older adults: analysis from the CHARIOT-PRO SubStudy.

Sujin Kang, Dimitra Kafetsouli, Jamie Ford, Janice Wong, Luc Bracoud, Joyce Suhy, Parthenia Giannakopoulou, Chi Udeh-Momoh, Tom C Russ, Craig Ritchie and 6 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sujin KangAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0000-0002-6715-8027
Dimitra KafetsouliAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0000-0003-1056-4718
Jamie FordAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0000-0003-0272-8313
Janice WongJohnson & Johnson, Cambridge, Cambridge, Massachusetts, USA.
Luc BracoudClario, Lyon, France.ORCID 0000-0001-7175-8781
Joyce SuhyClario, San Mateo, California, USA.
Parthenia GiannakopoulouAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0009-0003-8852-940X
Chi Udeh-MomohSchool of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.ORCID 0000-0002-7357-4692
Tom C RussDivision of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-9797-2188
Craig RitchieUniversity of St. Andrews, North Haugh, St. Andrews, UK.
Zoi AlexopoulouMerck Sharp & Dohme, London, UK.ORCID 0000-0002-1785-1800
Cristian SalinasTakeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.
Ziad S SaadJohnson & Johnson, San Diego, California, USA.
Gerald NovakJohnson & Johnson, Skillman, New Jersey, USA.
Oliver RobinsonAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0000-0002-4735-0468
Lefkos T MiddletonAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, London, UK.ORCID 0000-0002-8615-3723

Funding

Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Gates VenturesJanssen Research & Development, LLC, a Johnson & Johnson companyMerckNIA NIH HHS P30 AG072947NIHR ARC Dementia Fellowship NIHR200180TakedaUKRI Future Leaders Fellowship MR/S03532X/1UKRI Future Leaders Fellowship MR/Y02012X/1
6 · The paper itself

Abstract

introductionCerebral microhemorrhages (CMHs) and superficial siderosis (SS) are relatively common side effects of anti-amyloid immunotherapies, termed amyloid-related imaging abnormalities (ARIA-H). They are also observed in treatment-naïve older adults. This study explored relationships with modifiable and non-modifiable risk factors.

methodsThis cross-sectional study included 1414 cognitively unimpaired, treatment-naïve individuals aged 60 to 85 years from the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy. Relationships between CMHs/SS and cardiovascular risk factors, amyloid beta (Aβ) load, apolipoprotein E (APOE) ε4 status, educational attainment, and white matter hyperintensities were investigated using regression analyses and structural equation modeling.

resultsCMHs were observed in 8.3% of participants and SS in 1.3%. Significant risk factors for CMHs included age and hypertension. Higher education attainment appeared to have a protective effect. Elevated amyloid is a risk factor, particularly when adjusting for APOE ε4 status in individuals aged 70 or younger. DISCUSSION: Increasing age and hypertension are significant risk factors of CMHs. Higher educational attainment may offer a protective effect. HIGHLIGHTS: Of the 1414 participants from the CHARIOT-PRO SubStudy (CPSS), CMHs were present in 118 (8.3%), and SS was present in 18 (1.3%). Age and hypertension were identified as significant risk factors for CMHs, and the latter had a stronger association with the presence of CMHs among female participants. Having a bachelor's degree or higher was found to be protective. Elevated brain amyloid burden, particularly when adjusted for APOE ε4 carrier status, was identified as a risk factor in individuals aged 70 years and below.

Indexed as

Cerebral HemorrhageSiderosisAgedAged, 80 and overAmyloid beta-PeptidesApolipoprotein E4Cross-Sectional StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPrevalenceProspective StudiesRisk FactorsAmyloid beta-PeptidesApolipoprotein E4Alzheimer's diseaseamyloidamyloid‐related imaging abnormalitiesanti‐amyloid therapiesAPOE ε4ARIACAAcerebral microhemorrhagescognitively unimpaireddementiahypercholesterolemiahypertensionMRIPETsuperficial siderosiswhite matter hyperintensities

Identifiers

PMID40832697
PMCPMC12365613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.